Investigation of deodorizing effects of sofpyrronium bromide gel agent in patients with axillary osmidorosis and axillary hyperhidrosis

Investigation of deodorizing effects of sofpyrronium bromide gel agent - Investigation of deodorizing effects of sofpyrronium bromide gel agent

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049697

Enrollment

Registered

2022-12-05

Start date

2022-12-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osmidrosis, hyperhidrosis

Interventions

The effect after 2 weeks in the drug application group will be examined.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Diagnosed with Stage IV or higher axillary osmidrosis by gauze test and axillary hyperhidrosis of Hyperhidrosis Disease Severity Scale (HDSS) 3 or higher. 2) Wanting to treat axillary odor.

Exclusion criteria

Exclusion criteria: 1) Comorbid urination disorder due to enlarged prostate. 2) Comorbidity of angle-closure glaucoma. 3) Olfactory impairment. 4) There is a history of hypersensitivity to the components of this drug.

Design outcomes

Primary

Measure	Time frame
Percentage improvement in odor intensity assessment scores by study subjects	—

Countries

Japan

Contacts

Public ContactKenji Hayashida

Shimane University Plastic and Reconstructive Surgery

kenji@med.shimane-u.ac.jp0853232111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026